ARTICLE | Clinical News

Ethyol WR-2721 amifostine tissue protectant data

November 14, 1994 8:00 AM UTC

Interim data presented at the Chemotherapy Foundation Symposium in New York City found the combination therapy of Ethyol and chemotherapies to be highly active against the cancer.

Of 20 evaluable patients with advanced, localized lung cancer, 14 responded. Typical chemotherapy and radiation toxicities were encountered. One patient developed brain metastases during the radiation therapy (one month after the chemotherapy started). Mean followup on this trial was 24 months, and median survival was 17 months. Patients received 340 mg/m 2 of Ethyol four times a week for five weeks. ...